Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

Cancers·2026
Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
Same author

Gelatin Sponge-Embedded Adipose-Derived Stromal Cells Enable Allogeneic Application for Revascularization of Ischemic Wounds.

International journal of molecular sciences·2026
Same author

Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

相关实验视频

Updated: Sep 9, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

复发性/转移性头皮细胞癌患者的整体存活率在≥1次全身治疗后进展,使用MVX-ONCO-1,一种基于细胞封装的新型免疫疗法:SAKK 11/16的结果,IIa期试验

Eugenio Fernandez1,2, Rémi Vernet1,3,2, Muriel Urwyler1,3,2

  • 1Division of Oncology, Geneva University Hospitals, Geneva, Switzerland.

Experimental hematology & oncology
|August 31, 2025
PubMed
概括
此摘要是机器生成的。

新型癌症疫苗MVX-ONCO-1,结合自身瘤细胞和GM-CSF,在头癌患者中显示出有希望的生存率. 这种个性化疫苗引发了一种协调的免疫反应,作为一种独立的治疗方法提供了临床益处.

关键词:
晚期的固体瘤自主照射的瘤细胞细胞封装装置颗粒细胞巨细胞殖民地刺激因子免疫疗法

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

相关实验视频

Last Updated: Sep 9, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

科学领域:

  • 癌症学
  • 免疫疗法
  • 疫苗开发

背景情况:

  • 大多数癌症疫苗在临床上失败,
  • MVX-ONCO-1 是一种基于细胞的个性化疫苗,它结合了失活的自身瘤细胞和产生GM-CSF的基因细胞.
  • 这项技术能够持续地在当地提供强效的辅助剂,解决癌症疫苗开发中的关键未满足需求.

研究的目的:

  • 评估MVX-ONCO- 1在患有复发性/ 转移性头部和部状细胞癌 (R/ M HNSCC) 的患者中的疗效.
  • 在IIa期试验 (SAKK 11/16) 中评估整体存活率 (OS) 作为主要终点.

主要方法:

  • 进行了IIa期多中心试验 (SAKK 11/16).
  • 在至少一线全身治疗后进展的R/ M HNSCC患者被纳入.
  • 主要目标是让50%的患者在26周后活下来.

主要成果:

  • 该试验达到了主要终点,68. 8%的患者在6个月后存活,平均存活期为11. 4个月.
  • 在使用MVX-ONCO-1单一治疗时观察到完全和部分反应.
  • 在长期幸存者中发现了较高的抗体标位. 没有报告任何重大安全问题或制造问题.

结论:

  • MVX-ONCO-1 具有诱导协调免疫反应和延长独立治疗寿命的潜力.
  • 通过先前接触免疫检查点抑制剂,可以提高疫苗的疗效.
  • 临床试验注册:NCT02999646.